Entities / Company
Aptevo Therapeutics (United states).
company in Seattle, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Aptevo Therapeutics announced its expansion from its base in Seattle on September 4, 2025.Well supported13 reports
-
Trump-era tariffs benefit certain AI stocks, and Aptevo Therapeutics regained compliance with Nasdaq listing rules.Some support1 report
-
TipRanks provided investment data on Aptevo Therapeutics, noting an ongoing trial demonstrated a low cytokine release profile.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Aptevo Therapeutics (United states) this week
News at the entities that move Aptevo Therapeutics (United states) most-
ROTH Capital Partners TransactionalRoth Capital Partners has been engaged as a financial advisor for Aptevo Therapeutics Inc.Moves Aptevo Therapeutics (United states)
-
Seattle Shared contextSeattle Public Utilities plans to build a hub in North Seattle, leading to the displacement of Thompson's business.Moves Aptevo Therapeutics (United states)
Connections
The 4 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Marvin White Structural
Marvin White serves as the President and CEO of Aptevo Therapeutics.
-
Aptevo Therapeutics is subject to formal regulatory oversight and filing requirements by the Securities and Exchange Commission.
-
ROTH Capital Partners Transactional
ROTH Capital Partners served as the placement agent for Aptevo Therapeutics' offering.
-
Seattle Shared context
Aptevo Therapeutics operates and announces its activities within the geographical context of Seattle.
History
Events by the month they beganJune 2026
3 events- Aptevo Therapeutics announced its expansion from its base in Seattle on September 4, 2025.
- Trump-era tariffs benefit certain AI stocks, and Aptevo Therapeutics regained compliance with Nasdaq listing rules.
- TipRanks provided investment data on Aptevo Therapeutics, noting an ongoing trial demonstrated a low cytokine release profile.